Frontiers Case report: Short-term eculizumab use in atypical HUS

atypical hemolytic uremic syndrome - List of Frontiers' open access articles

Frontiers An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome

Frontiers Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19

The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

PDF] Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab

PDF] Post-streptococcal glomerulonephritis associated with atypical hemolytic uremic syndrome: to treat or not to treat with eculizumab?

PDF) Eculizumab use in a tertiary care nephrology center: data from the Vienna TMA cohort

PDF) Atypical hemolytic uremic syndrome in a patient with protein-losing enteropathy

Pregnancy associated atypical hemolytic uremic syndrome presenting with preeclampsia with HELLP syndrome and following treatment with Eculizumab

Short-term use of Soliris treats two cases of aHUS not tied to mutations

Frontiers Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis

Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era